ºÝºÝߣ

ºÝºÝߣShare a Scribd company logo
Research Progress

      Yuyun
MSC synchronization
                      (24h) 300.000cell/ml
                         in 60mm dish


  Treatment under                                Treatment under
  hypoxyc condition                             normoxyc condition
(2.2%oxygen, 5%CO2                                 (20% oxygen)
          )


                                                  24h incubation
  24h incubation
                       MSC proliferation &
                          viability, MSC
                      characterization, pluri
  48h incubation                                  48h incubation
                         potency marker



  72h incubation                                  72h incubation
Material & Method

Cell culture
                                          24h         48h      72h
                                         incub       incub    incub
 Four independent
                      MSC 1              ation       ation    ation
        MSC


                      MSC 2
                                24h          Normoxyc, 20% O2
   Media: DMEM-               synchro
  high glucose, FBS           nizati0n           Hypoxic 2.2%O2
                      MSC 3
     10%, NEAA
     0.1mM, b-
  mercaptoethanol     MSC 4               24h         48h      72h
   0.01mM, bFGF                          incub       incub    incub
    5ng/ml, EGF                          ation       ation    ation
       5ng/ml
Analysis Method

                            Trypan blue stained cell counted by
   Cell number &             automatic cell counting machine
      viability                        (invitrogen)



   MSC marker                       CD 44, CD 106 PCR



   Energy metabolism
                             HIF 1 A, HIF 1B, GLUT-1
  gene related glycolisis
                                       PCR
       mechanism


                               HIF 2A, Oct-4, Sox-
 Pluripotency marker
                                  2, Rex-1 PCR
RESULT

Cell proliferation & viability

              5,000,000

              4,500,000

              4,000,000

              3,500,000

              3,000,000
Cell number




              2,500,000

              2,000,000

              1,500,000

              1,000,000

               500,000

                     0




                                 Graph 1. Cell number profile
98%


                 96%


                 94%


                 92%
Cell viability




                 90%


                 88%


                 86%




                       Graph 2. Cell viability
ANOVA test comparing differences of cell proliferation rate &
                       viability between group
Compared group                         Mean between                 Significancy (p)
                                       group
Normoxyc & hypoxic viability           27.875                       0.000*

Normoxyc & hypoxic                     1.093                        0.000*
proliferation rate
Anova statistical analysis of cell proliferation rate & viability
expression, significant p<0.05, *statistically significant
MSC surface marker expression
HIF 1A & GLUT 1 expression




     Normoxic group          Hypoxic group
Densitometric analysis of HIF 1A
Densitometric analysis of
                             expression (ImageJ) N=normoxyc,
HIF 1A expression (ImageJ)
                             H=hypoxic
ANOVA test comparing differences HIF 1 A expression group (based on
densitometric analysis of HIF 1A expression by ImageJ)

Compared group                 Mean between group             Significancy (p)
MSC, normoxyc &hypoxic         1.044                          0.02*
treatment, 24hours
MSC, normoxyc &hypoxic         0.811                          0.02*
treatment, 48hours
MSC, normoxyc &hypoxic         0.000                          0.991
treatment, 72hours

Anova statistical analysis of HIF 1A expression, significant p<0.05, *statistically significant
ANOVA test comparing differences GLUT-1 expression group (based on
densitometric analysis of GLUT 1 expression by ImageJ)
Compared group                 Mean between group             Significancy (p)
MSC, normoxyc &hypoxic         2.617                          0.031*
treatment, 24hours
MSC, normoxyc &hypoxic         3.234                          0.046*
treatment, 48hours
MSC, normoxyc &hypoxic         2.403                          0.040*
treatment, 72hours
Anova statistical analysis of GLUT-1 expression, significant p<0.05, *statistically significant
HIF 2A Expression




 Normoxic group     Hypoxic group




                                    Densitometric analysis of HIF 1A expression
                                    (ImageJ) N=normoxyc, H=hypoxic
ANOVA test comparing differences of HIF 2A
                expression between group (based on densitometric
                     analysis of HIF 2A expression by ImageJ)

 Compared group                 Mean between group             Significancy (p)
 MSC, normoxyc &hypoxic         0.765                          0.040*
 treatment, 24hours
 MSC, normoxyc &hypoxic         1.887                          0.047*
 treatment, 48hours
 MSC, normoxyc &hypoxic         2.698                          0.047*
 treatment, 72hours

Anova statistical analysis of HIF 2A expression, significant p<0.05, *statistically significant
Pluripotency gene expression




     Normoxic group            Hypoxic group
Densitometric analysis of HIF 1A expression
(ImageJ) N=normoxyc, H=hypoxic
ANOVA test comparing differences of Oct 4
                expression between group (based on densitometric
                      analysis of Oct4 expression by ImageJ)

Compared group              Mean between group          Significancy (p)
MSC, normoxyc               0.347                       0.029*
&hypoxic treatment,
24hours
MSC, normoxyc               0.492                       0.015*
&hypoxic treatment,
48hours
MSC, normoxyc               0.603                       0.005*
&hypoxic treatment,
72hours

Anova statistical analysis of Oct4 expression, significant p<0.05, *statistically significant
ANOVA test comparing differences of Rex 1
                        expression between group (based on
                     densitometric analysis of Rex 1 expression by
                                       ImageJ)

   Compared group                Mean between group             Significancy (p)
   MSC, normoxyc &hypoxic        1.779                          0.049*
   treatment, 24hours
   MSC, normoxyc &hypoxic        2.881                          0.029*
   treatment, 48hours
   MSC, normoxyc &hypoxic        2.117                          0.006*
   treatment, 72hours

Anova statistical analysis of Rex1 expression, significant p<0.05, *statistically significant
RESEARCH PLAN
                            MTOR/                             HYPOXIA
                            MAPK
NORMOXIA                                acute                           chronic

                                                     HIF 3A
Proteosomal
degradation               HIF 1A               HIF 1A                   HIF 2A
                                             degradation                          HIF 1B


                                            HIF 1A
                    FIH
                                   HIF 1B              P3oo/CBP
                                                                        HIF target gene
     HIF 1A                                                                Cell cycle
                                                                         progression,
                                                HRE                      pluripotency,
Unstable HIF 1A lack of                                                 protooncogene
 binding to p300/CBP
                                       HIF-target gene
                                       (glycolysis, cell
                                           survival)
Plan


1. Focusing the study in cell proliferation and survival under
   hypoxic condition
2. Screen out glucose transporter gene expression: GLUT 1,
   GLUT 2, GLUT3, GLUT4
3. Check the expression of HIF 1B and HIF 3A
4. Confirming the cell culture in low glucose and high glucose
   medium
5. Screen out the expression of MAPK/MTOR related to
   energy metabolism sensing under hypoxic condition
6. Confirmation study using Real time PCR
Thank
you

More Related Content

Similar to Research progress by dr. Yuyun Rindiastuti (20)

Biological responses to tumor hypoxia & their potential as therapeutic targets
Biological responses to tumor hypoxia & their potential as therapeutic targetsBiological responses to tumor hypoxia & their potential as therapeutic targets
Biological responses to tumor hypoxia & their potential as therapeutic targets
MAASTRO clinic
?
METOXIA Framework and Hypoxia and Acidosis in Human Physiology and Diseases
METOXIA Framework and Hypoxia and Acidosis in Human Physiology and DiseasesMETOXIA Framework and Hypoxia and Acidosis in Human Physiology and Diseases
METOXIA Framework and Hypoxia and Acidosis in Human Physiology and Diseases
MAASTRO clinic
?
Lawrence Hightower
Lawrence HightowerLawrence Hightower
Lawrence Hightower
RosanePacheco73
?
HIF in cell Biology & Physiology
HIF in cell Biology & PhysiologyHIF in cell Biology & Physiology
HIF in cell Biology & Physiology
MAASTRO clinic
?
Gaming the System: Doping in Sports - Max gassmann
Gaming the System: Doping in Sports - Max gassmannGaming the System: Doping in Sports - Max gassmann
Gaming the System: Doping in Sports - Max gassmann
swissnex San Francisco
?
Reproducibility in Cellular Cancer Research: Providing Straightforward Soluti...
Reproducibility in Cellular Cancer Research: Providing Straightforward Soluti...Reproducibility in Cellular Cancer Research: Providing Straightforward Soluti...
Reproducibility in Cellular Cancer Research: Providing Straightforward Soluti...
Scintica Instrumentation
?
K Marcoe In Cell User Ge Meeting 2008
K Marcoe In Cell User Ge Meeting  2008K Marcoe In Cell User Ge Meeting  2008
K Marcoe In Cell User Ge Meeting 2008
KarenMarcoe
?
Clinical Imaging Hypoxia
Clinical Imaging HypoxiaClinical Imaging Hypoxia
Clinical Imaging Hypoxia
MAASTRO clinic
?
Energy system table
Energy system tableEnergy system table
Energy system table
Chris Lehner
?
What is hyperoxia, normoxia and hypoxia to cells: Why researchers should care...
What is hyperoxia, normoxia and hypoxia to cells: Why researchers should care...What is hyperoxia, normoxia and hypoxia to cells: Why researchers should care...
What is hyperoxia, normoxia and hypoxia to cells: Why researchers should care...
InsideScientific
?
Ricerca Early Safety Assays
Ricerca Early Safety AssaysRicerca Early Safety Assays
Ricerca Early Safety Assays
ShiminWang
?
Ricerca Early Safety Assays
Ricerca Early Safety AssaysRicerca Early Safety Assays
Ricerca Early Safety Assays
karenbernards
?
sodapdf-converted.pptx
sodapdf-converted.pptxsodapdf-converted.pptx
sodapdf-converted.pptx
EllyanaFarina1
?
Stephen Friend Complex Traits: Genomics and Computational Approaches 2012-02-23
Stephen Friend Complex Traits: Genomics and Computational Approaches 2012-02-23Stephen Friend Complex Traits: Genomics and Computational Approaches 2012-02-23
Stephen Friend Complex Traits: Genomics and Computational Approaches 2012-02-23
Sage Base
?
Un approccio integrato della biologia dei sistemi per studiare il trasporto d...
Un approccio integrato della biologia dei sistemi per studiare il trasporto d...Un approccio integrato della biologia dei sistemi per studiare il trasporto d...
Un approccio integrato della biologia dei sistemi per studiare il trasporto d...
CRS4 Research Center in Sardinia
?
What is hyperoxia, normoxia and hypoxia to cells
What is hyperoxia, normoxia and hypoxia to cellsWhat is hyperoxia, normoxia and hypoxia to cells
What is hyperoxia, normoxia and hypoxia to cells
Scintica Instrumentation
?
Applications and Clinical Consequences of Hypoxia inducible factor(HIF-1) ,th...
Applications and Clinical Consequences of Hypoxia inducible factor(HIF-1) ,th...Applications and Clinical Consequences of Hypoxia inducible factor(HIF-1) ,th...
Applications and Clinical Consequences of Hypoxia inducible factor(HIF-1) ,th...
MonoswiChakraborty
?
Tumour Hypoxia - detection and prognostic significance
Tumour Hypoxia - detection and prognostic significanceTumour Hypoxia - detection and prognostic significance
Tumour Hypoxia - detection and prognostic significance
MAASTRO clinic
?
Amira webinar
Amira   webinarAmira   webinar
Amira webinar
FHCCommunity
?
The Paradigm Shift from Normoxia to Physoxia: Enhancing Experimental Precisio...
The Paradigm Shift from Normoxia to Physoxia: Enhancing Experimental Precisio...The Paradigm Shift from Normoxia to Physoxia: Enhancing Experimental Precisio...
The Paradigm Shift from Normoxia to Physoxia: Enhancing Experimental Precisio...
Scintica Instrumentation
?
Biological responses to tumor hypoxia & their potential as therapeutic targets
Biological responses to tumor hypoxia & their potential as therapeutic targetsBiological responses to tumor hypoxia & their potential as therapeutic targets
Biological responses to tumor hypoxia & their potential as therapeutic targets
MAASTRO clinic
?
METOXIA Framework and Hypoxia and Acidosis in Human Physiology and Diseases
METOXIA Framework and Hypoxia and Acidosis in Human Physiology and DiseasesMETOXIA Framework and Hypoxia and Acidosis in Human Physiology and Diseases
METOXIA Framework and Hypoxia and Acidosis in Human Physiology and Diseases
MAASTRO clinic
?
HIF in cell Biology & Physiology
HIF in cell Biology & PhysiologyHIF in cell Biology & Physiology
HIF in cell Biology & Physiology
MAASTRO clinic
?
Gaming the System: Doping in Sports - Max gassmann
Gaming the System: Doping in Sports - Max gassmannGaming the System: Doping in Sports - Max gassmann
Gaming the System: Doping in Sports - Max gassmann
swissnex San Francisco
?
Reproducibility in Cellular Cancer Research: Providing Straightforward Soluti...
Reproducibility in Cellular Cancer Research: Providing Straightforward Soluti...Reproducibility in Cellular Cancer Research: Providing Straightforward Soluti...
Reproducibility in Cellular Cancer Research: Providing Straightforward Soluti...
Scintica Instrumentation
?
K Marcoe In Cell User Ge Meeting 2008
K Marcoe In Cell User Ge Meeting  2008K Marcoe In Cell User Ge Meeting  2008
K Marcoe In Cell User Ge Meeting 2008
KarenMarcoe
?
What is hyperoxia, normoxia and hypoxia to cells: Why researchers should care...
What is hyperoxia, normoxia and hypoxia to cells: Why researchers should care...What is hyperoxia, normoxia and hypoxia to cells: Why researchers should care...
What is hyperoxia, normoxia and hypoxia to cells: Why researchers should care...
InsideScientific
?
Ricerca Early Safety Assays
Ricerca Early Safety AssaysRicerca Early Safety Assays
Ricerca Early Safety Assays
ShiminWang
?
Ricerca Early Safety Assays
Ricerca Early Safety AssaysRicerca Early Safety Assays
Ricerca Early Safety Assays
karenbernards
?
Stephen Friend Complex Traits: Genomics and Computational Approaches 2012-02-23
Stephen Friend Complex Traits: Genomics and Computational Approaches 2012-02-23Stephen Friend Complex Traits: Genomics and Computational Approaches 2012-02-23
Stephen Friend Complex Traits: Genomics and Computational Approaches 2012-02-23
Sage Base
?
Un approccio integrato della biologia dei sistemi per studiare il trasporto d...
Un approccio integrato della biologia dei sistemi per studiare il trasporto d...Un approccio integrato della biologia dei sistemi per studiare il trasporto d...
Un approccio integrato della biologia dei sistemi per studiare il trasporto d...
CRS4 Research Center in Sardinia
?
What is hyperoxia, normoxia and hypoxia to cells
What is hyperoxia, normoxia and hypoxia to cellsWhat is hyperoxia, normoxia and hypoxia to cells
What is hyperoxia, normoxia and hypoxia to cells
Scintica Instrumentation
?
Applications and Clinical Consequences of Hypoxia inducible factor(HIF-1) ,th...
Applications and Clinical Consequences of Hypoxia inducible factor(HIF-1) ,th...Applications and Clinical Consequences of Hypoxia inducible factor(HIF-1) ,th...
Applications and Clinical Consequences of Hypoxia inducible factor(HIF-1) ,th...
MonoswiChakraborty
?
Tumour Hypoxia - detection and prognostic significance
Tumour Hypoxia - detection and prognostic significanceTumour Hypoxia - detection and prognostic significance
Tumour Hypoxia - detection and prognostic significance
MAASTRO clinic
?
The Paradigm Shift from Normoxia to Physoxia: Enhancing Experimental Precisio...
The Paradigm Shift from Normoxia to Physoxia: Enhancing Experimental Precisio...The Paradigm Shift from Normoxia to Physoxia: Enhancing Experimental Precisio...
The Paradigm Shift from Normoxia to Physoxia: Enhancing Experimental Precisio...
Scintica Instrumentation
?

Recently uploaded (20)

2309xx Scrips_IHLAD Board meeting_v1.3_SX (1).pptx
2309xx Scrips_IHLAD Board meeting_v1.3_SX (1).pptx2309xx Scrips_IHLAD Board meeting_v1.3_SX (1).pptx
2309xx Scrips_IHLAD Board meeting_v1.3_SX (1).pptx
Ravi Shah
?
leukoplakia, oral medicine and pathology, BDS
leukoplakia, oral medicine  and pathology, BDS leukoplakia, oral medicine  and pathology, BDS
leukoplakia, oral medicine and pathology, BDS
Syeda Ayesha Zarish
?
Guidance / Academic Advising, Counselling & Discipline .pptx
Guidance / Academic Advising, Counselling & Discipline .pptxGuidance / Academic Advising, Counselling & Discipline .pptx
Guidance / Academic Advising, Counselling & Discipline .pptx
Nandish Sannaiah
?
Antimicrobial Stewardship_ Role of the Pharmacist (1).pptx
Antimicrobial Stewardship_ Role of the Pharmacist (1).pptxAntimicrobial Stewardship_ Role of the Pharmacist (1).pptx
Antimicrobial Stewardship_ Role of the Pharmacist (1).pptx
Dr Arathy R Nath
?
X-ray Generators: Basic concepts and Application
X-ray Generators: Basic concepts and ApplicationX-ray Generators: Basic concepts and Application
X-ray Generators: Basic concepts and Application
Dr. Aryan (Anish Dhakal)
?
Pulmonary tuberculosis: A Radiology Perspective
Pulmonary tuberculosis: A Radiology PerspectivePulmonary tuberculosis: A Radiology Perspective
Pulmonary tuberculosis: A Radiology Perspective
Dr. Aryan (Anish Dhakal)
?
Code Of Federal Regulations and Federal Register
Code Of Federal Regulations and Federal RegisterCode Of Federal Regulations and Federal Register
Code Of Federal Regulations and Federal Register
Ms. Harshada Kiran Sonawane
?
3. Molecular Medicine the genetic basis of disease (unit 2) b .pptx
3. Molecular Medicine the genetic basis of disease (unit 2) b .pptx3. Molecular Medicine the genetic basis of disease (unit 2) b .pptx
3. Molecular Medicine the genetic basis of disease (unit 2) b .pptx
Bolan University of Medical and Health Sciences ,Quetta
?
lung cancer background Tim Mutafya. Global to local perpspectives. illustrati...
lung cancer background Tim Mutafya. Global to local perpspectives. illustrati...lung cancer background Tim Mutafya. Global to local perpspectives. illustrati...
lung cancer background Tim Mutafya. Global to local perpspectives. illustrati...
TimWiyuleMutafyaMD
?
1140523-¸ßÐÛµØÇøµÚ511´ÎС¶ù¿ÆÁªºÏ²¡ÀýÌÖÂÛ»á-¸ßÐÛÊÐÈî×ÛºÏÒ½Ôº.±è»å´Ú
1140523-¸ßÐÛµØÇøµÚ511´ÎС¶ù¿ÆÁªºÏ²¡ÀýÌÖÂÛ»á-¸ßÐÛÊÐÈî×ÛºÏÒ½Ôº.±è»å´Ú1140523-¸ßÐÛµØÇøµÚ511´ÎС¶ù¿ÆÁªºÏ²¡ÀýÌÖÂÛ»á-¸ßÐÛÊÐÈî×ÛºÏÒ½Ôº.±è»å´Ú
1140523-¸ßÐÛµØÇøµÚ511´ÎС¶ù¿ÆÁªºÏ²¡ÀýÌÖÂÛ»á-¸ßÐÛÊÐÈî×ÛºÏÒ½Ôº.±è»å´Ú
Ks doctor
?
THYROID GLAND -Prof.Dr.N.Mugunthan. KMMC,Muttom
THYROID GLAND  -Prof.Dr.N.Mugunthan. KMMC,MuttomTHYROID GLAND  -Prof.Dr.N.Mugunthan. KMMC,Muttom
THYROID GLAND -Prof.Dr.N.Mugunthan. KMMC,Muttom
Kanyakumari Medical Mission Research Center, Muttom
?
Breast practical on FA & CA .pptx
Breast practical on FA & CA          .pptxBreast practical on FA & CA          .pptx
Breast practical on FA & CA .pptx
Manjula N
?
EXPLORING THE ROLE OF PROBIOTICS AND POSTBIOTICS IN MODERN MEDICNE.pptx
EXPLORING THE ROLE OF PROBIOTICS AND POSTBIOTICS IN MODERN MEDICNE.pptxEXPLORING THE ROLE OF PROBIOTICS AND POSTBIOTICS IN MODERN MEDICNE.pptx
EXPLORING THE ROLE OF PROBIOTICS AND POSTBIOTICS IN MODERN MEDICNE.pptx
KeerthanaJagan
?
Physics of X-ray production by Dr. Aryan
Physics of X-ray production by Dr. AryanPhysics of X-ray production by Dr. Aryan
Physics of X-ray production by Dr. Aryan
Dr. Aryan (Anish Dhakal)
?
Dry Eye. A comprehensive overview on keratoconjunctivitis sicca
Dry Eye. A comprehensive overview on keratoconjunctivitis siccaDry Eye. A comprehensive overview on keratoconjunctivitis sicca
Dry Eye. A comprehensive overview on keratoconjunctivitis sicca
Aligarh Muslim University, Aligarh, Uttar Pradesh, India
?
Surveillance and Control of Multidrug-Resistant Organisms (MDROs): MRSA, VRE ...
Surveillance and Control of Multidrug-Resistant Organisms (MDROs): MRSA, VRE ...Surveillance and Control of Multidrug-Resistant Organisms (MDROs): MRSA, VRE ...
Surveillance and Control of Multidrug-Resistant Organisms (MDROs): MRSA, VRE ...
Adarsh Soman
?
2024 ESC Guidelines for the management of elevated HTN
2024 ESC Guidelines for the management of elevated HTN2024 ESC Guidelines for the management of elevated HTN
2024 ESC Guidelines for the management of elevated HTN
anjali909chanyal
?
Landmark breast cancer trials used in NCCN ,ESMO,ASCO
Landmark breast cancer trials used in NCCN ,ESMO,ASCOLandmark breast cancer trials used in NCCN ,ESMO,ASCO
Landmark breast cancer trials used in NCCN ,ESMO,ASCO
armin40254
?
X-ray interactions with matter by Dr. Aryan
X-ray interactions with matter by Dr. AryanX-ray interactions with matter by Dr. Aryan
X-ray interactions with matter by Dr. Aryan
Dr. Aryan (Anish Dhakal)
?
Collection, Transportation and Processing of Clinical Samples by Dhineshkumar...
Collection, Transportation and Processing of Clinical Samples by Dhineshkumar...Collection, Transportation and Processing of Clinical Samples by Dhineshkumar...
Collection, Transportation and Processing of Clinical Samples by Dhineshkumar...
DhineshkumarNpM
?
2309xx Scrips_IHLAD Board meeting_v1.3_SX (1).pptx
2309xx Scrips_IHLAD Board meeting_v1.3_SX (1).pptx2309xx Scrips_IHLAD Board meeting_v1.3_SX (1).pptx
2309xx Scrips_IHLAD Board meeting_v1.3_SX (1).pptx
Ravi Shah
?
leukoplakia, oral medicine and pathology, BDS
leukoplakia, oral medicine  and pathology, BDS leukoplakia, oral medicine  and pathology, BDS
leukoplakia, oral medicine and pathology, BDS
Syeda Ayesha Zarish
?
Guidance / Academic Advising, Counselling & Discipline .pptx
Guidance / Academic Advising, Counselling & Discipline .pptxGuidance / Academic Advising, Counselling & Discipline .pptx
Guidance / Academic Advising, Counselling & Discipline .pptx
Nandish Sannaiah
?
Antimicrobial Stewardship_ Role of the Pharmacist (1).pptx
Antimicrobial Stewardship_ Role of the Pharmacist (1).pptxAntimicrobial Stewardship_ Role of the Pharmacist (1).pptx
Antimicrobial Stewardship_ Role of the Pharmacist (1).pptx
Dr Arathy R Nath
?
X-ray Generators: Basic concepts and Application
X-ray Generators: Basic concepts and ApplicationX-ray Generators: Basic concepts and Application
X-ray Generators: Basic concepts and Application
Dr. Aryan (Anish Dhakal)
?
Pulmonary tuberculosis: A Radiology Perspective
Pulmonary tuberculosis: A Radiology PerspectivePulmonary tuberculosis: A Radiology Perspective
Pulmonary tuberculosis: A Radiology Perspective
Dr. Aryan (Anish Dhakal)
?
lung cancer background Tim Mutafya. Global to local perpspectives. illustrati...
lung cancer background Tim Mutafya. Global to local perpspectives. illustrati...lung cancer background Tim Mutafya. Global to local perpspectives. illustrati...
lung cancer background Tim Mutafya. Global to local perpspectives. illustrati...
TimWiyuleMutafyaMD
?
1140523-¸ßÐÛµØÇøµÚ511´ÎС¶ù¿ÆÁªºÏ²¡ÀýÌÖÂÛ»á-¸ßÐÛÊÐÈî×ÛºÏÒ½Ôº.±è»å´Ú
1140523-¸ßÐÛµØÇøµÚ511´ÎС¶ù¿ÆÁªºÏ²¡ÀýÌÖÂÛ»á-¸ßÐÛÊÐÈî×ÛºÏÒ½Ôº.±è»å´Ú1140523-¸ßÐÛµØÇøµÚ511´ÎС¶ù¿ÆÁªºÏ²¡ÀýÌÖÂÛ»á-¸ßÐÛÊÐÈî×ÛºÏÒ½Ôº.±è»å´Ú
1140523-¸ßÐÛµØÇøµÚ511´ÎС¶ù¿ÆÁªºÏ²¡ÀýÌÖÂÛ»á-¸ßÐÛÊÐÈî×ÛºÏÒ½Ôº.±è»å´Ú
Ks doctor
?
Breast practical on FA & CA .pptx
Breast practical on FA & CA          .pptxBreast practical on FA & CA          .pptx
Breast practical on FA & CA .pptx
Manjula N
?
EXPLORING THE ROLE OF PROBIOTICS AND POSTBIOTICS IN MODERN MEDICNE.pptx
EXPLORING THE ROLE OF PROBIOTICS AND POSTBIOTICS IN MODERN MEDICNE.pptxEXPLORING THE ROLE OF PROBIOTICS AND POSTBIOTICS IN MODERN MEDICNE.pptx
EXPLORING THE ROLE OF PROBIOTICS AND POSTBIOTICS IN MODERN MEDICNE.pptx
KeerthanaJagan
?
Surveillance and Control of Multidrug-Resistant Organisms (MDROs): MRSA, VRE ...
Surveillance and Control of Multidrug-Resistant Organisms (MDROs): MRSA, VRE ...Surveillance and Control of Multidrug-Resistant Organisms (MDROs): MRSA, VRE ...
Surveillance and Control of Multidrug-Resistant Organisms (MDROs): MRSA, VRE ...
Adarsh Soman
?
2024 ESC Guidelines for the management of elevated HTN
2024 ESC Guidelines for the management of elevated HTN2024 ESC Guidelines for the management of elevated HTN
2024 ESC Guidelines for the management of elevated HTN
anjali909chanyal
?
Landmark breast cancer trials used in NCCN ,ESMO,ASCO
Landmark breast cancer trials used in NCCN ,ESMO,ASCOLandmark breast cancer trials used in NCCN ,ESMO,ASCO
Landmark breast cancer trials used in NCCN ,ESMO,ASCO
armin40254
?
Collection, Transportation and Processing of Clinical Samples by Dhineshkumar...
Collection, Transportation and Processing of Clinical Samples by Dhineshkumar...Collection, Transportation and Processing of Clinical Samples by Dhineshkumar...
Collection, Transportation and Processing of Clinical Samples by Dhineshkumar...
DhineshkumarNpM
?

Research progress by dr. Yuyun Rindiastuti

  • 2. MSC synchronization (24h) 300.000cell/ml in 60mm dish Treatment under Treatment under hypoxyc condition normoxyc condition (2.2%oxygen, 5%CO2 (20% oxygen) ) 24h incubation 24h incubation MSC proliferation & viability, MSC characterization, pluri 48h incubation 48h incubation potency marker 72h incubation 72h incubation
  • 3. Material & Method Cell culture 24h 48h 72h incub incub incub Four independent MSC 1 ation ation ation MSC MSC 2 24h Normoxyc, 20% O2 Media: DMEM- synchro high glucose, FBS nizati0n Hypoxic 2.2%O2 MSC 3 10%, NEAA 0.1mM, b- mercaptoethanol MSC 4 24h 48h 72h 0.01mM, bFGF incub incub incub 5ng/ml, EGF ation ation ation 5ng/ml
  • 4. Analysis Method Trypan blue stained cell counted by Cell number & automatic cell counting machine viability (invitrogen) MSC marker CD 44, CD 106 PCR Energy metabolism HIF 1 A, HIF 1B, GLUT-1 gene related glycolisis PCR mechanism HIF 2A, Oct-4, Sox- Pluripotency marker 2, Rex-1 PCR
  • 5. RESULT Cell proliferation & viability 5,000,000 4,500,000 4,000,000 3,500,000 3,000,000 Cell number 2,500,000 2,000,000 1,500,000 1,000,000 500,000 0 Graph 1. Cell number profile
  • 6. 98% 96% 94% 92% Cell viability 90% 88% 86% Graph 2. Cell viability
  • 7. ANOVA test comparing differences of cell proliferation rate & viability between group Compared group Mean between Significancy (p) group Normoxyc & hypoxic viability 27.875 0.000* Normoxyc & hypoxic 1.093 0.000* proliferation rate Anova statistical analysis of cell proliferation rate & viability expression, significant p<0.05, *statistically significant
  • 8. MSC surface marker expression
  • 9. HIF 1A & GLUT 1 expression Normoxic group Hypoxic group
  • 10. Densitometric analysis of HIF 1A Densitometric analysis of expression (ImageJ) N=normoxyc, HIF 1A expression (ImageJ) H=hypoxic
  • 11. ANOVA test comparing differences HIF 1 A expression group (based on densitometric analysis of HIF 1A expression by ImageJ) Compared group Mean between group Significancy (p) MSC, normoxyc &hypoxic 1.044 0.02* treatment, 24hours MSC, normoxyc &hypoxic 0.811 0.02* treatment, 48hours MSC, normoxyc &hypoxic 0.000 0.991 treatment, 72hours Anova statistical analysis of HIF 1A expression, significant p<0.05, *statistically significant ANOVA test comparing differences GLUT-1 expression group (based on densitometric analysis of GLUT 1 expression by ImageJ) Compared group Mean between group Significancy (p) MSC, normoxyc &hypoxic 2.617 0.031* treatment, 24hours MSC, normoxyc &hypoxic 3.234 0.046* treatment, 48hours MSC, normoxyc &hypoxic 2.403 0.040* treatment, 72hours Anova statistical analysis of GLUT-1 expression, significant p<0.05, *statistically significant
  • 12. HIF 2A Expression Normoxic group Hypoxic group Densitometric analysis of HIF 1A expression (ImageJ) N=normoxyc, H=hypoxic
  • 13. ANOVA test comparing differences of HIF 2A expression between group (based on densitometric analysis of HIF 2A expression by ImageJ) Compared group Mean between group Significancy (p) MSC, normoxyc &hypoxic 0.765 0.040* treatment, 24hours MSC, normoxyc &hypoxic 1.887 0.047* treatment, 48hours MSC, normoxyc &hypoxic 2.698 0.047* treatment, 72hours Anova statistical analysis of HIF 2A expression, significant p<0.05, *statistically significant
  • 14. Pluripotency gene expression Normoxic group Hypoxic group
  • 15. Densitometric analysis of HIF 1A expression (ImageJ) N=normoxyc, H=hypoxic
  • 16. ANOVA test comparing differences of Oct 4 expression between group (based on densitometric analysis of Oct4 expression by ImageJ) Compared group Mean between group Significancy (p) MSC, normoxyc 0.347 0.029* &hypoxic treatment, 24hours MSC, normoxyc 0.492 0.015* &hypoxic treatment, 48hours MSC, normoxyc 0.603 0.005* &hypoxic treatment, 72hours Anova statistical analysis of Oct4 expression, significant p<0.05, *statistically significant
  • 17. ANOVA test comparing differences of Rex 1 expression between group (based on densitometric analysis of Rex 1 expression by ImageJ) Compared group Mean between group Significancy (p) MSC, normoxyc &hypoxic 1.779 0.049* treatment, 24hours MSC, normoxyc &hypoxic 2.881 0.029* treatment, 48hours MSC, normoxyc &hypoxic 2.117 0.006* treatment, 72hours Anova statistical analysis of Rex1 expression, significant p<0.05, *statistically significant
  • 18. RESEARCH PLAN MTOR/ HYPOXIA MAPK NORMOXIA acute chronic HIF 3A Proteosomal degradation HIF 1A HIF 1A HIF 2A degradation HIF 1B HIF 1A FIH HIF 1B P3oo/CBP HIF target gene HIF 1A Cell cycle progression, HRE pluripotency, Unstable HIF 1A lack of protooncogene binding to p300/CBP HIF-target gene (glycolysis, cell survival)
  • 19. Plan 1. Focusing the study in cell proliferation and survival under hypoxic condition 2. Screen out glucose transporter gene expression: GLUT 1, GLUT 2, GLUT3, GLUT4 3. Check the expression of HIF 1B and HIF 3A 4. Confirming the cell culture in low glucose and high glucose medium 5. Screen out the expression of MAPK/MTOR related to energy metabolism sensing under hypoxic condition 6. Confirmation study using Real time PCR